Sort
78,016 grants matching “breast cancer”
Project 3: Defining the appropriate context for targeting kinase signaling in combination with androgen receptor blockade to enhance therapeutic response in metastatic prostate cancer
$487,545Brett Stewart Carver · Sloan-Kettering Inst Can Research · U54 · FY2020 · CA
Virginia Mason Community Clinical Oncology Program
$487,529Jacqueline Vuky · Benaroya Research Inst At Virginia Mason · U10 · FY2010 · CA
PDGF-BB and the metastatic brain microenvironment
$487,490Gina Marie Sizemore · Ohio State University · R37 · FY2023 · CA
Targeting centrosomeâmitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.
$487,437Harold I Saavedra · Ponce School Of Medicine · R01 · FY2023 · CA
Developing novel bispecific antibodies for cancer treatment
$487,412Zhen Fan · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Project-005
$487,400Kunle O Odunsi · University Of Chicago · P30 · FY2023 · CA
Backup DNA repair in homologous recombination deficient cancers
$487,393Simon N Powell · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
UCSF-KAISER Building Interdisciplinary Research Careers in Women's Health Program
$487,392University Of California San Francisco · K12 · FY2005 · HD
REGIONAL VARIATIONS IN BREAST CANCER RATES IN CALIFORNIA
$487,389Public Health Institute · U01 · FY2001 · CA
PLEIOTROPHIN-- AN ANGIOGENIC SWITCH IN TUMOR PROGRESSION
$487,337Scripps Research Institute · R01 · FY2004 · CA
Research Project
$487,329Grace X Ma · Temple Univ Of The Commonwealth · U54 · FY2012 · CA
Genetics of RNA Tumor Viruses
$487,306G Steven Martin · University Of California Berkeley · R37 · FY2007 · CA
Dynamics of Tumor Stem Cells in Cancer Initiation, Therapy, and Resistance
$487,304Franziska Michor · Dana-Farber Cancer Inst · R01 · FY2011 · CA
Therapeutic and Diagnostic Factors as Related to Cancer Risk
$487,300Britton Trabert · Division Of Cancer Epidemiology And Genetics · ZIA · FY2018 · CA
The interplay of ion transporters and cytoskeleton in breast cancer migration and metastasis
$487,296Konstantinos Konstantopoulos · Johns Hopkins University · R01 · FY2022 · CA
Vanderbilt Network Lead Academic Participating Site for the NCTN
$487,276Jordan D Berlin · Vanderbilt University Medical Center · UG1 · FY2020 · CA
Vanderbilt Network Lead Academic Participating Site for the NCTN
$487,276Jordan D Berlin · Vanderbilt University Medical Center · UG1 · FY2019 · CA
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials
$487,259Nola M. Hylton · University Of California, San Francisco · R01 · FY2017 · CA
Long-term Survivorship in Older Women with Early Stage Breast Cancer
$487,245Rebecca A Silliman · Boston Medical Center · R01 · FY2011 · CA
Evidence-based Dissemination for Mammography Adherence in Safety Net Communities
$487,242Linda D Highfield · University Of Texas Hlth Sci Ctr Houston · R18 · FY2016 · HS
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
$487,223Runhua Runa Liu · University Of Alabama At Birmingham · R01 · FY2020 · CA
Breast Cancer Survival: Lifestyle and Genetic Determinants
$487,221Xiao-Ou Shu · Vanderbilt University · R01 · FY2009 · CA
DEVELOPMENT OF NOVEL DRUGS FOR HIGH RISK TRIPLE NEGATIVE BREAST CANCER TREATMENT
$487,200Regents Of The University Of Minnesota · · FY2015 · Department of the Army
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY
$487,193Gregory M Lanza · Washington University · R01 · FY2011 · CA
SYRACUSE HEMATOLOGY-ONCOLOGY CCOP
$487,182Hematology-Oncology Associates/Ctl Ny · U10 · FY2000 · CA